The Diabetic Peripheral Neuropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Peripheral Neuropathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued products.
GlobalData tracks 36 drugs in development for Diabetic Peripheral Neuropathy by 27 companies/universities/institutes. The top development phase for Diabetic Peripheral Neuropathy is preclinical with 13 drugs in that stage. The Diabetic Peripheral Neuropathy pipeline has 34 drugs in development by companies and two by universities/ institutes. Some of the companies in the Diabetic Peripheral Neuropathy pipeline products market are: Praetego, Sino Biopharmaceutical and Vertex Pharmaceuticals.
The key targets in the Diabetic Peripheral Neuropathy pipeline products market include Sodium Channel Protein Type 10 Subunit Alpha, Transient Receptor Potential Cation Channel Subfamily V Member 1, and Mu Type Opioid Receptor.
The key mechanisms of action in the Diabetic Peripheral Neuropathy pipeline product include Sodium Channel Protein Type 10 Subunit Alpha Blocker with three drugs in Phase II. The Diabetic Peripheral Neuropathy pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Diabetic Peripheral Neuropathy pipeline products market including Small Molecule, and Gene Therapy.
Diabetic Peripheral Neuropathy overview
Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet; pain or discomfort in the feet or legs, including prickly, sharp pain or burning feet; muscle weakness and loss of muscle tone in the feet and lower leg; loss of balance; dry feet; and cracked skin. The predisposing factors include diabetes, smoking, and kidney diseases. Treatment includes antidepressants, anti-seizure drugs, and opioid analgesics.
For a complete picture of Diabetic Peripheral Neuropathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
